Clinical observation of anlotinib in the treatment of lung cancer with brain metastasis and refractory peritumoral edema

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061517

Enrollment

Unknown

Registered

2022-06-27

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with metastatic lung cancer who have previously received at least 2 systemic treatments; 2. Brain metastasis and severe peritumoral edema were confirmed by magnetic resonance examination of the brain. 3. Aged between 18 and 70; 4. The expected survival time is more than 3 months; 5. No dysfunction of vital organs, liver and kidney functions, blood routine and electrolytes were basically normal.

Exclusion criteria

Exclusion criteria: 1. Pregnancy and lactation; 2. Evidence or suspicion of alcohol or drug abuse; 3. Participation in this study may lead to any unnecessary risk as determined by the researcher; 4, Anlotinib hydrochloride allergy should be contraindicated; 5. Patients with central lung squamous cell carcinoma or large hemoptysis risk are contraindicated; 6. Patients with severe liver and kidney insufficiency.

Design outcomes

Primary

Measure	Time frame
The degree of peritumoral edema;Quality of life status;	—

Secondary

Measure	Time frame
Therapeutic effective rate;	—

Countries

China

Contacts

Public ContactSong Haixia

Gansu Cancer Hospital

280062353@qq.com+86 13639397387

Outcome results